Buccal Film vs IV Palonosetron for Prevention of CINV in Cancer Patients Receiving MEC
Status:
Not yet recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
The phase 3 study is to compare the efficacy and safety of palonosetron, a long-acting 5-HT3
receptor antagonist, by buccal film delivery compared to IV injection for the prevention of
chemotherapy-induced nausea and vomiting. Subjects receive a single dose of palonosetron
prior to moderately emetogenic chemotherapy.